



BioBridges 2026

September 24–25 ● Prague, Czech Republic



Scientific program

Thursday, September 24

9:00–10:30 Morning session 1

Update on regulatory landscape – use of in vitro similarity comparison
René Anour (AGES) 45 min.

Industry perspective and scientific background for current in vitro similarity comparison
Martin Schiestl (Sandoz) 45 min.

10:30–11:00 Coffee break

11:00–12:30 Morning session 2

PBPK biologics rituximab and small molecules
Ondřej Slanař (Institute of Pharmacology, 1st Faculty of Medicine, Charles University) 45 min.

Physiologically Based Biopharmaceutics Model of Apixaban application to strength biowaiver
Paulo Paixão (Pharmacy Faculty of Lisbon University) 45 min.

12:30–14:00 Lunch

14:00–15:30 Afternoon session 1

ICH M12 interactions and its interpretation
Carolien Versantvoort (MEB) 45 min.

PPI interactions modeling
Esther Lubberts (MEB) 45 min.

15:30–16:00 Coffee break

16:00–17:30 Afternoon session 1

To pool, or not to pool, that is the question...
Helmut Schütz (BEBAC) 45 min.



BioBridges 2026

September 24–25 ● Prague, Czech Republic



Complex developments - LAI, the role of partial AUCs

Lida Kalantzi (Pharmathen)

45 min.

19:30–22:30 Networking dinner

Friday, September 25

9:00–10:30 Morning session 1

Topicals LALA, ophthalmics

Peter Caspers (MEB)

45 min.

Application of regulatory landscape for LALA - ophthalmics (cry or not to cry...:-)

Marina Feřtek, Nora Šotolová (Synavia)

45 min.

10:30–11:00 Coffee break

11:00–12:30 Morning session 2

Intranasal suspension

Jean Michel Cardot (SAS Borvo)

45 min.

Mastering IVRT and IVPT: From technical complexity to Scientific confidence

Magali Breisse (Eurofins)

45 min.

12:30–14:00 Lunch